We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Circulating Microvesicle-Based Assay Is Potential Prostate Cancer Diagnostic

By LabMedica International staff writers
Posted on 26 May 2011
A circulating microvesicle ("cMV")-based test is a potentially powerful diagnostic tool for detecting prostate cancer.

cMVs are sub-cellular membrane-bound vesicles, ranging from 30 nm to 1,500 nm in size, that are found circulating in the blood and other body fluids. More...
They are released from various cell types under both normal and pathologic conditions, including cancer. Each population of cMV expresses an array of proteins which reflects its cell-of-origin.

Carisome Technology is a versatile blood-based, highly reproducible testing technology. The technology platform identifies and characterizes cMVs, creating disease-specific, cMV-based biosignatures, which can be made up of a combination of biomarkers. The unique cMV biosignature can then be used for the diagnosis, prognosis, and measurement of therapeutic response.

The assay that enables the isolation, capture, and characterization of cMVs specific to prostate cancer was developed by Caris Life Sciences (Dallas, TX, USA). It has potential to deliver more accurate diagnoses for men with prostate cancer than current methods.

A poster highlighting the potential of the circulating microvesicle (cMV)-based prostate cancer test was presented at the American Urological Association (AUA) 2011 Annual Meeting, which was held in Washington DC (USA) from May 14-19, 2011.

Related Links:

Caris Life Sciences



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.